Elarofiban

CAS No. 198958-88-2

Elarofiban( —— )

Catalog No. M34233 CAS No. 198958-88-2

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 603 Get Quote
5MG 922 Get Quote
10MG 1226 Get Quote
25MG 1794 Get Quote
50MG 2410 Get Quote
100MG 3177 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Elarofiban
  • Note
    Research use only, not for human use.
  • Brief Description
    Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.
  • Description
    Elarofiban (RWJ-53308) is a nonpeptide, orally active fibrinogen receptor antagonist. Elarofiban has the potential for platelet mediated thrombotic disorders research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    198958-88-2
  • Formula Weight
    416.51
  • Molecular Formula
    C22H32N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](NC(=O)[C@H]1CN(C(CCC2CCNCC2)=O)CCC1)(CC(O)=O)C=3C=CC=NC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Judith H. Cohen, et al. A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban. Organic Process Research & Development 2003, 7, 866-872.
molnova catalog
related products
  • Tirofiban

    A potent, selective inhibitor of the platelet fibrinogen receptor GPIIb/IIIa with IC50 of 9 nM.

  • RO0270608

    RO0270608, the active metabolite of R411, is an orally active dual α4β1/α4β7 integrin antagonist with anti-inflammatory properties, useful for studying allergic inflammatory responses.

  • DS-70

    DS-70 (α4 integrin inhibitor DS-70) is a novel potent α/β- peptidomimetic antagonist of α4 integrin.